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Cerebral vein thrombosis has been well recognized for nearly two centuries. However, therapeutic options for the condition are
limited due to lack of large randomized trials. The various modalities reportedly used include antiplatelets, anticoagulation,
fibrinolysis, and mechanical thrombectomy. Of these, antiplatelets are the least studied, and there are only anecdotal reports
of aspirin use. Anticoagulation is the most widely used and accepted modality with favorable outcomes documented in two
randomized controlled trials. Various fibrinolytic agents have also been tried. Local infusions have shownmore promise compared
to systemic agents. Similarly, mechanical thrombectomy has been used to augment the eﬀects of chemical thrombolysis. However,
in the absence of randomized controlled trials; there is no concrete evidence of the safety and eﬃcacy of either of these modalities.
Limited study series disclosed that decompression surgery in malignant CVT can be life saving and provides good neurological
outcome in some cases. Conclusion. Overall therapeutics for CVT need larger randomized controlled trials. Anticoagulaion with
heparin is the only modality with a reasonable evidence to support its use in CVT. Endovascular thrombolysis and mechanical
thrombectomy are reserved for selected cases who fail anticoagulation and decompression surgery for malignant CVT with
impending herniation.
1. Introduction
Cerebral venous thrombosis (CVT) is a well-recognized
condition presenting in multiple diﬀerent forms. It was first
described in 1825 [1] in a man who suﬀered from headaches,
seizures, and delirium for six months. His autopsy revealed
superior sagittal sinus thrombosis. Since that initial descrip-
tion nearly two centuries ago, several case reports and case
series have come out, but the condition continues to be a
diagnostic and therapeutic challenge.
The estimated incidence is about 2 to 4/million/year [2]
and about 75% of these are reportedly women [3]. A recent
study in children <18 years found a higher incidence of
6.7/million/year [4]. Also CVT seems to be a bigger problem
in the Asian world compared to the west. A report from India
by Panagariya et al. suggests that CVT accounts for up to 40%
of strokes in women and 50% of all young strokes [5, 6].
Risk factors for CVT have been highlighted in several
studies and case series. The largest trial to date was the Inter-
national study on cerebral vein and dural sinus thrombosis
(ISCVT) [7]. This was a prospective, observational study
from 21 diﬀerent countries in which 624 patients with CVT
were followed up for 16months. In this study, 43.6% patients
had more than one risk factors. The commonest cause was
genetic or acquired thrombophilia (34.1%), followed by use
of oral contraceptives or hormonal replacement therapy
(58.6% of female patients) and local or systemic infection in
12.3%.
Another study carried out by Khealani et al. reported
systemic and central nervous system infection as the com-
monest predisposing cause in patients from Pakistan and
Middle East. These were followed by postpartum state,
homocysteinemia, and genetic thrombophilia. The contribu-
tion of oral contraceptive pill use was much lower at 3% [8].
The etiologic factors are therefore diverse and may
remain obscure in up to 40%, most of whom are believed
to have a genetic predisposition [9]. Broadly speaking, the
common settings for CVT are puerpurium, infectious and
inflammatory disease, malignancy, and oral contraceptives
use [10]. CVT presents most commonly with headaches,
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focal or generalized seizures, neurologic deficits, or coma
[11–14].
The course of the illness in CVT varies with death and
dependency rates ranging from 8 to 40% [7, 15–17]. The
ISCVT has identified several predictors of poor outcome,
most notable being older age (>37 years), male gender,
seizures at admission, rapid evolution of thrombosis, the
presence of focal deficits, and CNS infection and cancer [7].
Therapeutic options for CVT have been explored in
several studies. At present, anticoagulation is the mainstay
of treatment. However, ∼40% of patients with CVT have
concomitant propensity for intracranial hemorrhage and
hence the apprehension on the part of the clinicians.
In this paper, we intend to review the evidence for and
against the available therapeutic options for CVT.
2. General Measures
The most dreaded complications of CVT are intracranial
hypertension and cerebral herniation. The raised intracranial
pressure is secondary to obstructed venous drainage leading
to cerebral edema and intracranial hemorrhage which is
often accompanying this condition. A review paper on
mechanisms of damage in CVT [18] highlights multiple
factors such as increased pressure in the dural sinus as well
as increased venous flow velocities, rate of occlusion of
the sinus, and superimposed cytotoxic as well as vasogenic
edema. The paper also suggests that the extent of damage
depends on the rate at which occlusion occurs and collaterals
are formed.
Hydration is of paramount importance when patients
present with signs and symptoms suggestive of CVT. Dehy-
dration will make the condition worse by making the
hypercoagulability worse.
Another important measure to prevent sudden elevations
of intracranial pressure would be to give antiepileptic cover
to these patients. Focal or generalized seizures are more
frequent in CVT than in any other type of stroke and this
includes status epilepticus. The ISCVT reported seizures
in 39% of their patients. Again no consensus exists on
use of antiepileptic agents in CVT, but the risk is higher
for those who present initially with seizures and in those
who have supratentorial brain lesions including hemorrhage
and edema [19]. The risk of developing seizures after
CVT diagnosis is very low in patients who do not have
these risk factors. Therefore, for the high-risk group, we
would recommend antiepileptic drug use. The guidelines for
treatment of seizures and for status epilepticus are the same
as the standard epilepsy guidelines.
In this acute phase, medical management to decrease
intracranial pressure (ICP) is recommended. This includes
head elevation, hyperventilation to a target PaCO2 of 30–
35mmHg, and use of mannitol [20].
Glucocorticoids like dexamethasone are used by many
for controlling ICP. There is, however, no randomized trial
to prove their eﬃcacy. A study [21] analyzed data from the
ISCVT on the use of glucocorticoids and failed to find any
benefit. Therefore, routine use of these agents cannot be
recommended.
It is not known whether use of mannitol or hyper-
ventilation improves outcomes, but it definitely buys time
before a more definitive procedure for controlling ICP (like
hematoma evacuation and decompressive craniectomy) can
be undertaken. There are no randomized controlled trials to
support their use, however.
Isolated intracranial hypertension is also a well-recog-
nized form of presentation in patients with CVT [22]. Given
the diﬀerence in prognosis, its management also diﬀers from
simple management of intracranial hypertension, which
includes measures to decrease ICP. For those with under-
lying venous thrombosis, in addition to these measures,
anticoagulation is recommended although more aggres-
sive measures like mechanical thrombectomy are seldom
required.
3. Specific Measures
These would be tailored around the underlying cause of
cortical venous thrombosis. The major causes include pro-
thrombotic conditions, either genetic or acquired which are
the commonest cause, oral contraceptives and other drugs
that cause a hypercoagulable state, pregnancy and the puer-
perium, malignancy, infections including CNS infections,
ear, sinus, mouth, face, and neck infections and even systemic
infectious disease, head injury, and mechanical precipitants
like lumbar puncture and neurosurgical procedures [7].
For genetic prothrombotic conditions, there is no specific
therapy available. For acquired conditions, it is tailored
accordingly. For drug-induced CVT, the drug has to be
discontinued along with other measures that follow in this
paper. Malignancy requires its own specific therapy besides
treatment for CVT.
Spread of infection from a contiguous site is a well-
known cause of dural sinus thrombosis. Particularly impor-
tant sources are mastoidits and other middle-ear infections
as well as ethmoid and frontal sinusitis. For these infec-
tions, leading to septic dural sinus thrombosis, high-dose
antibiotics are the mainstay of treatment. Additionally, local
collections of pus at these sites may have to be drained.
Anticoagulation is not well studied but has been used
particularly in cavernous sinus thrombosis with good results
[23, 24]. For lateral and superior sagittal sinus thrombosis,
the data is even more sparse with mixed results [25, 26].
Therefore, till more evidence is available, the physician will
have to balance the risk of benefit of anticoagulation with the
risk of hemorrhage in septic dural sinus thrombosis.
Patients with nephrotic syndrome have a much higher
incidence of arterial as well as venous thrombosis compared
to the general population [27]. There are several underlying
mechanisms that lead to this increased risk. The general
therapeutic measures for treatment of CVT in patients with
nephrotic syndrome do not diﬀer from management of the
condition due to other causes. However, the underlying
disease condition leading to nephrotic syndrome has to be
separately addressed. Those patients who achieve remission
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of nephrotic syndrome may discontinue anticoagulation
after six months following remission if there is no other
indication for anticoagulation.
4. Antiplatelets
There are only anecdotal reports of use of aspirin for cortical
venous thrombosis. No randomized trial or even a case series
exist on the use of antiplatelet agents.
5. Anticoagulation
In 1941, Lyons [28] for the first time described the successful
use of heparin in cerebral venous thrombosis. He reported
two cases of infective cavernous sinus thrombosis that greatly
benefited from a combination of antibiotics and heparin.
In 1985, Bousser et al. [29] retrospectively reviewed
38 patients with angiographically proven cerebral venous
thrombosis. Twenty three of these patients received heparin,
and clinical improvement was reported in all with 19 making
a complete recovery. No deaths occurred in the heparin
arm, and based on these findings the authors concluded
that heparin was both safe and eﬃcacious in patients with
CVT.
In 1991, the first randomized controlled trial [15] on
anticoagulation in CVT was published. Twenty patients with
aseptic CVT were randomized, 10 to a placebo arm and 10 to
heparin arm. A CVT severity scale was used to monitor the
clinical course. Patients in the heparin arm showed a clear
improvement at day 3 (P < .05), and the diﬀerence remained
significant after 8 days of treatment (P< .01). After 3 months,
8 of the heparin-treated patients had a complete clinical
recovery, and 2 had slight residual neurological deficits. In
the placebo group, only 1 patient had a complete recovery, 6
patients had neurological deficits, and 3 patients died (P less
than.01). Three patients in the treatment group and 2 in the
control group had ICH when therapy was started. However,
no new cases of ICH occurred after initiation of heparin.
Three patients in the control group experienced a new or
worsened hemorrhage.
In this same report [15], Einhaupl et al. described
an additional retrospective study on the relation between
heparin treatment and ICH in CVT patients. 43 patients
with CVT and ICH were studied. 27 of these patients were
treated with dose-adjusted intravenous heparin after the
ICH. Of these 27 patients, 4 died (mortality 15%), and 14
patients completely recovered. Of the 13 patients that did
not receive heparin after ICH, 9 died (mortality 69%) and
only 3 patients completely recovered. The authors concluded
that anticoagulation with dose-adjusted intravenous heparin
is an eﬀective treatment in patients with CVT and that ICH is
not a contraindication to heparin treatment in these patients.
The study was criticized for its small sample size, use of an
outcome measure that was not previously validated, and a
significant delay from symptom onset to the initiation of
therapy.
The other randomized trial to improve on the results of
the above trial came in 1999 [30]. This was a double-blind
placebo-controlled multicenter trial. Thirty patients were
randomized to subcutaneous nadroparin (180 antifactor Xa
units/kg per 24 hours) and 29 to matching placebo for 3
weeks (double-blind part of trial), followed by 3 months of
oral anticoagulants for patients allocated nadroparin (open
part). Patients with cerebral hemorrhage caused by sinus
thrombosis were also included. After 3 weeks, 6 of 30 patients
(20%) in the nadroparin group and 7 of 29 patients (24%)
in the placebo group had a poor outcome, defined as death
or Barthel Index score of <15 (risk diﬀerence, −4%; 95%
CI, −25 to 17%; NS). After 12 weeks, 4 of 30 patients
(13%) in the nadroparin group and 6 of 29 (21%) in the
placebo group had a poor outcome, defined as death or
Oxford Handicap Score of ≥3 (risk diﬀerence, − 7%; 95%
CI, − 26% to 12%; NS). There were no new symptomatic
cerebral hemorrhages. One patient in the nadroparin group
had a major gastrointestinal hemorrhage, and 1 patient
in the placebo group died from clinically suspected pul-
monary embolism. Authors concluded that patients with
cerebral sinus thrombosis treated with anticoagulants (low-
molecular-weight heparin followed by oral anticoagulation)
had a favorable outcome more often than controls, but the
diﬀerence was not statistically significant. Anticoagulation
proved to be safe, even in patients with cerebral hemorrhage.
A Cochrane review [2] was published in 2005 using these
two trials for meta-analysis, and this concluded that based
upon the limited evidence available, anticoagulant treatment
for cerebral sinus thrombosis appeared to be safe and was
associated with a potentially important reduction in the
risk of death or dependency which did not reach statistical
significance.
The results from the ISCVT [7] also support the use of
anticoagulation, as in a retrospective review done recently
showed a nonsignificant but definite trend towards improve-
ment with anticoagulation.
No trials have compared unfractionated heparin with
low-molecular-weight heparin.
The recently published EFNS guidelines [20] based
on Cochrane review; MEDLINE search; Cochrane Central
Register of Controlled Trials (CENTRAL) recommend that
anticoagulation should be given to all patients with CVT
who do not have contraindications for anticoagulation.
The recommended duration of oral anticoagulation varies
depending on the underlying etiology. For transient risk
factors, the recommendation is for 3 months, for idiopathic
variety and for mild thrombophilia, 6–12 months, and for
those with recurrent episodes of CVT or severe throm-
bophilia, the therapy should continue indefinitely.
Most of the reviews suggest that anticoagulation is
safe even in patients who have evidence of intracranial
hemorrhage, be it intracranial or subarachnoid.
In one review published by Wasay and Kamal in 2008
[31] on anticoagulation, however, the authors were strongly
of the opinion that in the absence of randomized trials
and hence statistical significance, anticoagulation cannot be
recommended across the board for all CVT patients. They
have stressed on studies where patients have recanalized even
in the absence of any treatment.
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In the Paediatric population, uncertainty regarding the
therapeutic options continues. In the International Paedi-
atric Stroke study [32], 84 neonates were diagnosed with
CVT from 10 countries. In these patients, there were
significant diﬀerences regarding use of antithrombotics and
their indications. A recent single center prospective study
[33] evaluated the safety and eﬃcacy of anticoagulation
in neonates and children and concluded that in this age
group also, AC is safe and nontreatment results in thrombus
propagation.
Based on these trials and reviews, anticoagulation con-
tinues to be the mainstay of treatment for CVT.
6. Fibrinolytic Agents
Despite the use of anticoagulant therapy, some patients
continue to worsen. For these patients, use of fibrinolytic
agents, particularly locally, has been tried.
For many years, agents like urokinase and streptokinase
were of interest for clot lysis. Initially, people tried systemic
urokinase and reported mixed results [34, 35]. A series
of 5 patients aﬀected by aseptic dural sinus thrombosis
were treated with a combination of heparin sodium and
urokinase, and complete clinical recovery was reported [36].
Then in the late 80s, some investigators tried local instead of
systemic urokinase. In 1988 to improve the safety profile, a
patient with dural sinus thrombosis was successfully treated
with local urokinase infusion continued for 8 hours [37]. The
patient recovered with very minimal deficits despite a small
temporal hemorrhage.
Following this report, several case reports and series with
this modality were published. Barnwell and colleagues [38]
reported three patients who were treated with a transjugular
direct infusion of urokinase. The period of infusion ranged
from 4 to 10 days. Two patients had both angiographic
and clinical improvement of signs and symptoms, whereas
the third only showed angiographic improvement. Another
series reported seven patients treated with direct infusion
of urokinase into the thrombosed sinus. The duration of
infusion was a mean of 163 hours. All had angiographic
improvement, and six out of seven had clinical benefit also
[39].
In 1995, Horowitz et al. [40] reported a case series of
12 patients with CVT treated with selective catheterization
and urokinase infusion. 4 of these had hemorrhages on pre-
infusion scans. Despite this, there was no major therapeutic
morbidity. Eleven out of the 12 patients had sinus patency
restored, and 10 of these had excellent clinical outcome.
For superior sagittal sinus thrombosis, Wasay et al.
[41] conducted a nonrandomized comparison of local
urokinase infusion with systemic heparin anticoagulation.
Forty patients were enrolled, 20 received local urokinase
followed by systemic heparin, and 20 received only systemic
heparin. Discharge neurological function was better in the
thrombolysis group than in the heparin group (P = .019),
but hemorrhagic complications were also more with the
thrombolysis group (P = .49). The authors concluded that
local urokinase may be superior to systemic heparin alone
in the treatment of superior sagittal sinus thrombosis.
Other agents have also been tried for thrombolysis. In
one patient, local thrombectomy followed by streptokinase
infusion proved very beneficial [42]. In yet another series
[43], 12 patients were treated with local recombinant tissue
plasminogen activator along with systemic heparin. The
authors concluded that this combination shows promise but
should be reserved for those without obvious hemorrhage.
The time taken to restore flowwas faster than with urokinase.
Subsequently, a systematic review was published in 2003
[44] that included cases of cerebral venous and dural
sinus thrombosis treated with fibrinolytics. 72 studies were
included and no randomized clinical trial was found. Uroki-
nase was the thrombolytic most frequently administered
(76%) and majority had it locally infused (88%). ICH was
reported in 17% of the patients, and in 5% it caused clinical
deterioration. The conclusion, however, was that although
thrombolytics appeared to be safe, their eﬃcacy cannot be
assessed from the published literature.
In 2004, Cochrane review [45] also failed to identify any
randomized controlled trial on thrombolytic use in CVT and
concluded that there is no concrete evidence of the safety and
eﬃcacy of thrombolytic therapy in dural sinus thrombosis.
More recently, some more reviews have come out on
the use of local thrombolytics. A series of 168 patients of
CVT [46] treated with individualized endovascular treat-
ment was published in January 2009. These included direct
thrombolysis via internal jugular vein, injection of urokinase
via common carotid artery, and stent angioplasty in venous
sinus. They reported favorable outcomes with these indi-
vidualized procedures. Another Chinese study [47] reported
five patients with deteriorating neurological condition who
underwent endovascular thrombolysis. The recovery was
excellent in four of the five patients; one, however, could not
be saved despite a decompressive craniectomy.
In November 2009, another review of studies done on
thrombolysis was published [48]. The authors concluded
that although there was some evidence of beneficial eﬀects
of chemical thrombolysis from the reported literature, there
is a need for prospective trials. Till then most institutions
continue to combine direct thrombolysis with systemic anti-
coagulation. An evenmore recent experience with 19 patients
from India [49] suggests that intrasinus thrombolysis is safe
and eﬀective in patients with CVT who fail to respond to the
conventional anticoagulation.
Based on the available evidence and in the absence of any
randomized controlled trial on fibrinolytic use in CVT, its
safety and eﬃcacy are still questionable.
7. Mechanical Thrombectomy
Mechanical thrombectomy has been used to augment the
eﬀects of chemical thrombolysis and sometimes to avoid
fibrinolytics due to high risk of hemorrhage. Severalmethods
have been tried for mechanical thrombectomy. These include
balloon angioplasty, stenting, clot maceration, and rheolytic
thrombectomy [50, 51].
In 2003, Soleau et al. [52] published a review of 31
patients retrospectively evaluated from one institution. Four
treatment strategies were identified, and complications and
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clinical outcomes were assessed for each group. Chemical
thrombolysis was very eﬀective in restoring sinus patency;
however, 30% experienced hemorrhagic complications. 60%
in this group made good clinical recovery. Patients who
underwent mechanical thrombectomies demonstrated low
hemorrhagic complications, and 88% had good clinical
recovery.
Kirsch et al. in 2007 [51] published a retrospective review
of four patients with CVT treated with transfemoral intra-
venous rheolytic thrombectomy. All four had good restora-
tion of blood flow, and in three it was completely normalized.
In these three, there was a rapid clinical improvement
also. The authors concluded that this was a safe and ef-
fective method for selected patients with dural venous sinus
thrombosis.
There is only a single prospective review of endovascular
treatment in CVT which was published in 2008 [53]. 20
patients were enrolled, 12 of those were comatose, and 14
had hemorrhagic infarcts before thrombolysis. Thrombolysis
was done by introducing a catheter through the internal
jugular vein into the superior sagittal sinus, most underwent
thrombosuction with a rheolytic catheter, combined with
thrombectomy with a Fogarty catheter, followed by uroki-
nase infusion. 6 patients died, 5 of whom had large infarcts
and impending herniation even prior to thrombolysis.
The authors concluded that thrombolysis can be eﬀective
for severe sinus thrombosis, but patients may deteriorate
because of increased cerebral hemorrhage.
Therefore, endovascular therapy is a promising modality
but lacks randomized controlled trials for its evaluation.
However, the available evidence supports its use along with
chemical thrombolysis as well as alone for treatment of
selected cases of CVT.
8. Decompressive Surgery
This modality has limited utilization so far in the treatment
of CVT. Decompression has been used in cases of malignant
elevations in intracranial pressure to abort impending herni-
ation. Despite treatment with endovascular thrombolytics, it
was observed that there was poor outcome in patients with
impending herniation. For these patients, decompressive
craniectomy was introduced. Coutinho et al. [54] reports
3 such patients who underwent decompression, two had
excellent outcome, the third died.
Another prospective series [55] of three patients with
malignant sinus thrombosis reported good recovery in two of
these patients, and one was left with moderate disability. The
authors reviewed prior literature on decompressive surgeries
in these patients between 1970 and 2008. Eight such patients
had been reported in three reviews [56–58], and the outcome
in four was good. Three patients were left with moderate
and one with severe disability. The authors concluded that
decompressive surgery in these patients with severe CVT and
evidence of malignant intracranial hypertension can be life
saving, and the outcome can also be reasonably good.
A retrospective review [59] of 12 patients with malignant
cerebral venous thrombosis has recently been published.
Of these, 8 underwent decompressive surgery. The four
patients who did not undergo surgery died. Of these 8 who
did, one died of pulmonary embolism, but the other 7 not
just survived, but 6 of them made excellent neurological
recovery.
Based on the current available literature, decompressive
surgery can be a very promising option for patients with
malignant cerebral venous thrombosis.
9. Conclusion
After reviewing all the available therapeutic modalities for
CVT, the question remains which modality to use in which
situation. Generally speaking, the choice of therapy, which
is at the discretion of the treating physician in the absence
of clear cut guidelines, depends largely on the clinical
presentation. This may vary from mild headache to focal
deficits and even coma. The presentation broadly speaking
can be acute, subacute, or chronic. For subacute or chronic
cases, headache is often the most prominent presenting
feature, and the need is for urgent but not emergent therapy.
Anticoagulation with heparin is the best studied and the only
recommended therapy in these cases. Acute presentation
can be more striking with encephalopathy and focal deficits
dominating the picture. In these patients, again the best
evidence is in favor of anticoagulation, but more aggressive
measures to recannulate the sinus may be undertaken in
case the patient continues to deteriorate. These include
endovascular thrombolysis and mechanical thrombectomy.
Escalation of therapy is recommended in case of clinical
worsening. A patient presenting with mild symptoms may
just be managed on anticoagulation. However, if there is
evidence of deterioration in terms of new deficits and
drowsiness, therapy may be escalated to use of systemic or
local thrombolytics, and in the presence of intracranial hem-
orrhage and malignant intracranial hypertension, surgical
options may also be considered.
To summarize, overall therapeutics for CVT need larger
randomized controlled trials. Anticoagulation with heparin
is the only modality with reasonable evidence to support
its use in CVT, even in patients with cerebral hemorrhage.
Endovascular thrombolysis is a promising option for patients
with a severe form of CVT or following a failure of antico-
agulation therapy. Mechanical thrombectomy is reserved for
selected cases and decompression surgery for malignant CVT
with impending herniation.
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